-

07:23:06 PM

BWV Stock News

BWV - Blue Water Vaccines Inc

03/09/23 8:30 AM

Nasdaq : BWV

earningslow float

Blue Water Vaccines Reports Year 2022 Financial Results and Recent Business Highlights

Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced its financial results for the fiscal year ended December 31, 2022 and provided an update on recent business developments and Company progress. Blue Water

RHEA-AI

neutral

02/06/23 10:15 AM

Nasdaq : BWV

managementlow float

Blue Water Vaccines Appoints Seasoned Commercial Operations Leader Frank Jaeger as Senior Vice President of Marketing and Business Development

Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced the appointment of Frank Jaeger, seasoned commercial operations and business development executive, as Senior Vice President of Marketing and Business

RHEA-AI

neutral

02/01/23 9:15 AM

Nasdaq : BWV

partnershiplow float

Blue Water Vaccines Announces Partnership with AbVacc for Joint Development of Novel Monkeypox and Marburg Vaccine Candidates

Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced a collaboration with AbVacc, Inc.

RHEA-AI

neutral

01/17/23 8:30 AM

Nasdaq : BWV

managementlow float

Blue Water Vaccines Announces Appointment of Seasoned Public Market and Private Equity Investment Leader Timothy Ramdeen to Board of Directors

Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the appointment of Timothy Ramdeen, seasoned

RHEA-AI

neutral

01/09/23 8:30 AM

Nasdaq : BWV

conferenceslow float

Blue Water Vaccines to Present at Biotech Showcase 2023 During the 41st Annual J.P. Morgan Healthcare Conference Week in San Francisco

Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that BWV management will present at the

RHEA-AI

neutral

12/12/22 8:30 AM

Nasdaq : BWV

low float

Blue Water Vaccines Announces Institutional Research Coverage by Two Notable Healthcare-Focused Wall Street Banks, Receives “Buy” Rating From Both

Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced its first analyst coverage since going public

RHEA-AI

neutral

12/06/22 8:30 AM

Nasdaq : BWV

low float

Blue Water Vaccines Organizes Key Opinion Leader Event to Discuss Unmet Need for Acute Otitis Media and Pneumonia Vaccine and Its Streptococcus pneumoniae Vaccine Candidate

Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”) a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the Company will host an online Key Opinion

RHEA-AI

neutral

12/01/22 8:30 AM

Nasdaq : BWV

conferenceslow float

Blue Water Vaccines to Present Update on Novel, Live Attenuated, Intranasally Delivered Streptococcus pneumoniae Vaccine to Prevent Acute Otitis Media, Pneumococcal Pneumonia, and Invasive Pneumococcal Disease at the World Vaccine & Immunotherapy Congress West Coast 2022

Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced that Ali Fattom, Ph.D., will present at the World Vaccine & Immunotherapy Congress West Coast 2022 in San Diego, California on Thursday, December 1, 2022. Dr.

RHEA-AI

neutral

11/10/22 8:47 AM

Nasdaq : BWV

buybackearningslow float

Blue Water Vaccines Reports Third Quarter 2022 Financial Results and Recent Business Highlights; Announces 5 Million Share Repurchase Program

Closed private placement in August 2022, with net proceeds of approximately $8.7 million Announced plans to evaluate efficacy of BWV-201 for protection against non-invasive pneumococcal pneumonia in children and adults Board of Directors authorized a 5 million share repurchase program in November

RHEA-AI

neutral

11/08/22 8:30 AM

Nasdaq : BWV

managementlow float

Blue Water Vaccines Announces Appointment of Vuk Jeremić, Previous Chair of the Council of Europe’s Committee of Ministers and Previous President of the United Nations General Assembly, to Its Board of Directors

Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the appointment of seasoned advisor and

RHEA-AI

neutral